Texas Yale Capital Corp. decreased its position in shares of PerkinElmer, Inc. (NYSE:PKI) by 50.0% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 9,000 shares of the medical research company’s stock after selling 9,000 shares during the period. Texas Yale Capital Corp.’s holdings in PerkinElmer were worth $867,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of PKI. Geode Capital Management LLC increased its holdings in shares of PerkinElmer by 8.9% during the fourth quarter. Geode Capital Management LLC now owns 1,522,499 shares of the medical research company’s stock worth $119,450,000 after buying an additional 124,168 shares in the last quarter. Artisan Partners Limited Partnership increased its holdings in shares of PerkinElmer by 42.3% during the first quarter. Artisan Partners Limited Partnership now owns 408,941 shares of the medical research company’s stock worth $39,406,000 after buying an additional 121,552 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of PerkinElmer by 59.3% during the fourth quarter. Deutsche Bank AG now owns 177,244 shares of the medical research company’s stock worth $13,919,000 after buying an additional 65,985 shares in the last quarter. Nikko Asset Management Americas Inc. acquired a new stake in shares of PerkinElmer during the first quarter worth approximately $4,516,000. Finally, Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of PerkinElmer during the first quarter worth approximately $4,487,000. 95.99% of the stock is owned by institutional investors.
PKI has been the subject of several recent analyst reports. Wood & Company reaffirmed an “average” rating and set a $49.00 price objective on shares of PerkinElmer in a report on Friday, July 19th. Raymond James initiated coverage on shares of PerkinElmer in a research note on Wednesday, July 10th. They set an “outperform” rating on the stock. Zacks Investment Research raised shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $89.00 price target on the stock in a research note on Thursday, May 30th. ValuEngine cut shares of PerkinElmer from a “buy” rating to a “hold” rating in a research note on Wednesday, July 31st. Finally, Goldman Sachs Group raised shares of PerkinElmer from a “neutral” rating to a “buy” rating and set a $115.00 price target on the stock in a research note on Tuesday, April 9th. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $78.58.
PerkinElmer (NYSE:PKI) last announced its quarterly earnings data on Monday, July 29th. The medical research company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.01). PerkinElmer had a net margin of 9.01% and a return on equity of 16.07%. The business had revenue of $722.50 million during the quarter, compared to the consensus estimate of $729.10 million. During the same period in the previous year, the business posted $0.91 earnings per share. PerkinElmer’s revenue was up 2.7% compared to the same quarter last year. As a group, analysts anticipate that PerkinElmer, Inc. will post 4.04 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 8th. Shareholders of record on Friday, October 18th will be paid a $0.07 dividend. The ex-dividend date is Thursday, October 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.34%. PerkinElmer’s payout ratio is presently 7.76%.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Read More: What is a Reverse Stock Split?
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.